Donanemab
Treatment for Alzheimer's Disease
Typical Dosage: 700 mg IV every 4 weeks for first 3 doses, then 1400 mg IV every 4 weeks
Effectiveness
57%
Safety Score
48%
Clinical Trials
10
Participants
3.5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
48
DangerousModerateSafe
Treatment Details
Dosage Range
700 mg IV every 4 weeks for first 3 doses, then 1400 mg IV every 4 weeks
Time to Effect
6-12 months
Treatment Duration
Until amyloid clearance (6-18 months), then monitoring
Evidence Quality
MODERATENumber Needed to Treat (NNT)
9(Treat 9 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
4(Treat 4 patients to see 1 additional serious adverse event)
Confidence Score
78%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$27,500
Monitoring:$8,000
Side Effect Mgmt:$2,500
Total Annual:$38,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$600,000/QALY
QALYs Gained
0.22
Comparison vs No treatment / symptomatic treatment
Cost Difference
+$38,000/year
More expensive
QALY Difference
+0.22 QALYs
Better outcomes
Dominance
No dominance
Donanemab Outcomes
for Alzheimer's Disease
Efficacy Outcomes
Overall Effectiveness
+57%
Common Side Effects
ARIA-E (edema)
+24%
ARIA-H (hemorrhage)
+31%
Headache
+10%
Infusion-related reactions
+8.7%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
10 active trials recruiting for Donanemab in Alzheimer's Disease
A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease
NCT06996730NOT YET RECRUITINGPHASE2, PHASE3
240 participants
INTERVENTIONAL
Medellín, Colombia
Started: Jan 15, 2026
Alzheimer's Tau Platform: Regimen A - AADvac1
NCT07167966NOT YET RECRUITINGPHASE2
450 participants
INTERVENTIONAL
Started: Jun 30, 2026
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
NCT05026866ACTIVE NOT RECRUITINGPHASE3
3K participants
INTERVENTIONAL
Birmingham, United States +215 more
Started: Aug 27, 2021
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
NCT04437511ACTIVE NOT RECRUITINGPHASE3
1.74K participants
INTERVENTIONAL
Gilbert, United States +273 more
Started: Jun 19, 2020
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
NCT05508789RECRUITINGPHASE3
1.5K participants
INTERVENTIONAL
ABB, Argentina +140 more
Started: Oct 10, 2022
A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease
NCT06566170RECRUITING
6.25K participants
OBSERVATIONAL
Huntsville, United States
Started: Oct 7, 2024
Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation
NCT06911944NOT YET RECRUITINGPHASE4
60 participants
INTERVENTIONAL
Started: Aug 1, 2026
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
NCT05738486ACTIVE NOT RECRUITINGPHASE3
1.18K participants
INTERVENTIONAL
Chandler, United States +48 more
Started: Feb 28, 2023
Alzheimer's Tau Platform: Master Protocol
NCT06957418NOT YET RECRUITINGPHASE2
900 participants
INTERVENTIONAL
Started: Jun 30, 2026
Making Antibody Treatments More Effective in Early Alzheimer's Disease Using 3Tesla Magnetica Resonance
NCT07456462NOT YET RECRUITINGNA
50 participants
INTERVENTIONAL
Milan, Italy
Started: May 1, 2026
Completed Clinical Trials
3 completed trials for Donanemab in Alzheimer's Disease
A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)
NCT03367403COMPLETEDPHASE2
272 participants
INTERVENTIONAL
Phoenix, United States +60 more
Started: Dec 18, 2017
A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)
NCT05108922COMPLETEDPHASE3
148 participants
INTERVENTIONAL
Fullerton, United States +30 more
Started: Nov 16, 2021
A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)
NCT04640077COMPLETEDPHASE2
95 participants
INTERVENTIONAL
Phoenix, United States +26 more
Started: Nov 23, 2020